Hikal vs Peers
- Market cap
- ₹2,660 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹155.32 – ₹291.22
Hikal ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Hikal. Its P/E of 22.5 compares with a peer median of 22.5.
Hikal vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Hikal | 215.72 | -4.23% | 2,660 | 22.5 | 2.85 | 14.5% | +18.5% |
| Hikal | 215.72 | -4.23% | 2,660 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Hikal peer comparison — frequently asked questions
Who are Hikal's competitors?
Hikal's listed peers in Drug Manufacturers - Specialty & Generic include Hikal, ranked here by market capitalisation.
How does Hikal's P/E compare with its peers?
Hikal trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Hikal's peers?
By market capitalisation, the largest company in the group is Hikal at ₹2,660 crore, against ₹2,660 crore for Hikal.
Same Data For Peers
Trade Hikal With ATS
Track HIKAL live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.